U.S. Northeast Remains Life-Science Darling, Attracting $8 Billion in Capital Investment
Attachment: US Northeastern Pharma-Biotech Projects, Sep 2014
SUGAR LAND--September 11, 2014--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Like any long-term union, the one shared between the U.S. Northeast region, which comprises Delaware, New Jersey, New York and Pennsylvania, and the Life Science Industry is a classic example of a love/hate relationship. The Northeast region has been pummeled over the past few years with scores of pharmaceutical plants closing and lucrative jobs lost. On the other hand, the region remains a favorite for capital investment from both the private and public sectors for new and upgraded life-science manufacturing plants and research centers. Currently, there are 147 active reported projects translating to a hefty $7.8 billion in total investment value.
Within this article: Details on the Pharmaceutical-Biotech Industry's development in the U.S. Northeast, and key projects from major players such as City University of New York and Merck & Company (NYSE:MRK).
